Abrocitinib
Overview
Abrocitinib is an oral selective inhibitor of Janus kinase 1 (JAK1), approved for the treatment of moderate-to-severe atopic dermatitis. It works by modulating the immune response involved in the pathogenesis of the disease.
API suppliers (4)
Suppliers of Abrocitinib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 3 of 4 suppliers.
3 of 4 hold a GMP certificate on record in the EU or UK registers
- MAITHRI DRUGS PRIVATE LTDIndia1 active DMF GMP on record
- MOEHS IBERICA SLSpain1 active DMF GMP on record
- CHANGZHOU PHARMACEUTICAL FACTORYChina1 active DMF GMP on record
- Micro Labs Usa1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Abrocitinib expires 14 Jan 2036 and exclusivity 14 Jan 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Abrocitinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.